My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 667

    1.

    Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.

    Devereux RB, Dahlöf B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Helle Berg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE Study Group.

    Ann Intern Med. 2003 Aug 5;139(3):169-77.PMID: 12899584 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.

    Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE (Losartan Intervention for Endpoint Reduction) Study Group.

    JAMA. 2002 Sep 25;288(12):1491-8.PMID: 12243636 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]

    Ibsen H, Pedersen OL, Dahlöf B, Kjeldsen SE, Lindholm LH.

    Ugeskr Laeger. 2003 Jan 27;165(5):456-9. Danish. PMID: 12599843 [PubMed - indexed for MEDLINE]Related articles

    4.

    Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

    Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group.

    Lancet. 2002 Mar 23;359(9311):995-1003.PMID: 11937178 [PubMed - indexed for MEDLINE]Related articles

    5.

    Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

    Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB.

    J Am Coll Cardiol. 2005 Mar 1;45(5):712-9.PMID: 15734615 [PubMed - indexed for MEDLINE]Related articles

    6.

    Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

    Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group.

    Lancet. 2002 Mar 23;359(9311):1004-10.PMID: 11937179 [PubMed - indexed for MEDLINE]Related articles

    7.

    Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.

    J Am Coll Cardiol. 2005 Mar 1;45(5):705-11.PMID: 15734614 [PubMed - indexed for MEDLINE]Related articles

    8.

    Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.

    Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Devereux RB, Fyhrquist F, Ibsen H, Kjeldsen SE, Dahlöf B.

    Hypertension. 2005 Sep;46(3):492-9. Epub 2005 Aug 22.PMID: 16116047 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.

    Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.

    Curr Med Res Opin. 2007 Feb;23(2):259-70.PMID: 17288679 [PubMed - indexed for MEDLINE]Related articles

    10.

    Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.

    Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B; LIFE Study Group.

    J Hypertens. 2005 Jul;23(7):1425-31.PMID: 15942467 [PubMed - indexed for MEDLINE]Related articles

    11.

    Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.

    Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB.

    Hypertension. 2005 Jan;45(1):46-52. Epub 2004 Dec 6.PMID: 15583076 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]

    Ibsen H, Lindholm LH, Pedersen OL, Dahlöf B, Kjeldsen S.

    Ugeskr Laeger. 2003 Jan 27;165(5):459-62. Danish. PMID: 12599844 [PubMed - indexed for MEDLINE]Related articles

    13.

    Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

    Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group.

    JAMA. 2003 Apr 23-30;289(16):2073-82.PMID: 12709465 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.

    Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group.

    Hypertension. 2005 Apr;45(4):580-5.PMID: 15790960 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Prognostic significance of left ventricular mass change during treatment of hypertension.

    Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B.

    JAMA. 2004 Nov 17;292(19):2350-6.PMID: 15547162 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators.

    JAMA. 2004 Nov 17;292(19):2343-9.PMID: 15547161 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.

    Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H.

    Am Heart J. 2009 Jan;157(1):177-84. Epub 2008 Oct 17.PMID: 19081416 [PubMed - indexed for MEDLINE]Related articles

    18.

    An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.

    Boersma C, Carides GW, Atthobari J, Voors AA, Postma MJ.

    Clin Ther. 2007 May;29(5):963-71.PMID: 17697915 [PubMed - indexed for MEDLINE]Related articles

    19.

    The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.

    Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.

    Am J Hypertens. 1997 Jul;10(7 Pt 1):705-13.PMID: 9234823 [PubMed - indexed for MEDLINE]Related articles

    20.

    Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

    Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.

    Hypertension. 1998 Dec;32(6):989-97.PMID: 9856962 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity